Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide (n = 6 RCTs), exenatide (n = 3 RCTs), dulaglutide (n = 1 RCT) or semaglutide (n = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy (n = 2 RCTs) or imaging techniques (n = 9 RCTs). Compared to placebo or reference therapy, treatment with GLP-1 RAs for a median of 26 weeks was associated with significant reductions in the absolute percentage of liver fat content on magnetic resonance-based techniques (pooled weighted mean difference: −3.92%, 95% confidence intervals (CI) −6.27% to −1.56%) and serum liver enzyme levels, as well as with greater histological resolution of NASH without worsening of liver fibrosis (pooled random-effects odds ratio 4.06, 95% CI 2.52–6.55; for liraglutide and semaglutide only). In conclusion, treatment with GLP-1 RAs (mostly liraglutide and semaglutide) is a promising treatment option for NAFLD or NASH that warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent meta‐analysis consisting of 11 RCTs that investigated GLP‐1 agonists in NAFLD patients concluded that their overall clinical effect lies mainly in NASH resolution rather than fibrosis improvement [42].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The average HbA1c reduction with GLP-1RA in MASLD studies was estimated to be 0.5 % in individuals with and without type 2 diabetes [104] but may be substantially higher depending on the investigated compound and collective [105].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Specifically, the interpretation of the I 2 -statistics is as follows: I 2 -values of roughly 25% show low heterogeneity, I 2 -values of roughly 50% show medium heterogeneity, whereas I 2 -values of roughly 75% show high heterogeneity [65].”
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“We performed a systematic review and meta-analysis of RCTs in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (http://www.prisma-statement.org) [61].”
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 2×
“In addition, for continuous variables, if not available, SDs of the mean differences were estimated using the following formula: SD = [(SD pre-treatment) 2 + (SD post-treatment) 2 − (2R × SD pre-treatment × SD post-treatment)] 12 [64].”
InfluentialLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Cited by
Items 101–200 of 299
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2070473 · Cited by 27
Role of metformin in the management of type 2 diabetes: recent advances
Gonzalez-Lopez, C., & Wojeck, B. S. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16511 · Cited by 28
Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD
Jirapinyo, P., Jaroenlapnopparat, A., Zucker, S. D., & Thompson, C. C. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07178-5 · Cited by 22
“…fibrosis demonstrated that compared to placebo or the standard of care, GLP-1RAs were associated with significant reductions in liver enzyme levels and liver fat on magnetic resonance–based imaging techniques, as well as greater histological resolution of MASH without worsening of fibrosis [13].”
Manka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 24
Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells
Koda, Y., Nakamoto, N., & Kanai∥, T. (2022) · Seminars in Liver Disease · doi:10.1055/a-1957-6384 · Cited by 21
Gurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Cheraghpour, M., Hatami, B., & Singal, A. G. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.09.041 · Cited by 21
Gad, A. I., Ibrahim, N. F., Almadani, N. A., Mahfouz, R., Nofal, H. A. E., Elrafey, D. S., Ali, H. T., Elhawary, A. T., & Sadek, A. M. E. M. (2024) · Diseases · doi:10.3390/diseases12080186 · Cited by 24
“A recent meta-analysis showed a correlation between a reduction in hepatic fat content and a reduction in BMI [40].”
MethodCurrent status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis
Shi, Y., & Fan, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00822-1 · Cited by 21
“Exenatide, tirzepatide and dulaglutide all had potential efficacy in reducing the liver fat content and serum liver enzyme levels as well as histological improvement of NASH [44, 45].”
BackgroundErrafii, K., Khalifa, O., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051020 · Cited by 17
Napoli, R., Avogaro, A., Formoso, G., Piro, S., Purrello, F., Targher, G., & Consoli, A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.039 · Cited by 18
Self-citationPotential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH)
Wang, Z., Zhao, Z., Xia, Y., Cai, Z., Wang, C., Shen, Y., Liu, R., Qin, H., Jia, J., & Yuan, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01773-y · Cited by 19
“In addition, GLP-1 RAs is considered a promising treatment option for NASH and deserves further investigation [11, 12].”
BackgroundGalatou, E., Mourelatou, E. A., Hatziantoniou, S., & Vizirianakis, I. S. (2022) · Antioxidants · doi:10.3390/antiox11061060 · Cited by 19
Soresi, M., & Giannitrapani, L. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i30.3541 · Cited by 20
“A meta-analysis of randomized controlled trials found that liraglutide and semaglutide improved MRI-assessed steatosis, the histological signs of NASH, but confirmed no improvement in fibrosis[25].”
Chen, W., Ng, H.-J., Jao, A.-T., Wu, S., & Soong, R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112407 · Cited by 21
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Tsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
Savino, A., Loglio, A., Neri, F., Camagni, S., PASULO, L., Lucà, M. G., Trevisan, R., FAGIUOLI, S., & Viganò, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133871 · Cited by 15
Danpanichkul, P., Suparan, K., Kaeosri, C., Jatupornpakdee, P., Attia, A. M., Suenghataiphorn, T., Thongpiya, J., Sukphutanan, B., Huang, D. Q., Noureddin, M., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.10.026 · Cited by 21
Tirzepatide adds hepatoprotection to its armoury
Targher, G. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00074-2 · Cited by 17
Self-citationAhmed, N. R., Kulkarni, V. V., Pokhrel, S., Akram, H., Abdelgadir, A., Chatterjee, A., & Khan, S. (2022) · Cureus · doi:10.7759/cureus.24829 · Cited by 17
“Semaglutide achieved greater weight loss than OCA without a significant rebound weight gain after drug cessation [12,15-17].”
InfluentialLi, Y., Lei, R., Lei, H., Qin, X., Xie, F., Yao, C., & Feng, P. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002471 · Cited by 15
Amatya, R., Lee, D.-H., Min, K. A., & Shin, M. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071963 · Cited by 15
“According to the report by Finan, the GLP-1R/GIPR dual-agonists could provide more significant hypoglycemic, hyperlipidemic, and anti-obesity effects compared with single agonists with attenuated gastrointestinal discomfort and nausea (typically associated with GLP-1R agonists) [48].”
BackgroundTwo sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis
Zhu, B., Wu, H., Li, K. S., Eisa-Beygi, S., Singh, B., Bielenberg, D. R., Huang, W., & Chen, H. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107249 · Cited by 15
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
Ciardullo, S., Morieri, M. L., DANIELE, G., Fiorentino, T. V., Mezza, T., Tricò, D., Consoli, A., Prato, S. D., Giorgino, F., Piro, S., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02300-6 · Cited by 19
Dusilová, T., Kovář, J., Laňková, I., Thieme, L., Hubáčková, M., Šedivý, P., Pajuelo, D., Burian, M., Dezortová, M., Miklánková, D., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206100 · Cited by 16
“These drugs, originally intended for the treatment of diabetes due to their incretin action, effectively reduce body weight and liver fat content [5–7].”
BackgroundPradhan, R., Yin, H., Lu, S., Sebastiani, G., Yu, O. H. Y., Suissa, S., & Azoulay, L. (2025) · Diabetes Care · doi:10.2337/dc24-1903 · Cited by 16
Friesen, C. S., Hosey, C. M., Chan, S. S., Csanaky, I. L., Wagner, J. B., Sweeney, B. R., Friesen, A., Fraser, J. D., & Shakhnovich, V. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.663351 · Cited by 18
Ordóñez-Vázquez, A. L., Gall, S. M.-B., Pal, S. C., & Méndez‐Sánchez, N. (2022) · Medical Science Monitor · doi:10.12659/msm.938365 · Cited by 17
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 17
Schäfer, Z., Mathisen, A., Thomsen, T. R., Rossing, P. R., & Kirketerp‐Møller, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110799 · Cited by 15
“Promising results have been shown for DM2 patients with a high risk of cardiovascular diseases (CVD) [6], treatment of other diseases such as dementia, obesity, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [8 – 10].”
Malandris, K., Papandreou, S., Avgerinos, I., Karagiannis, T., Paschos, P., Michailidis, T., Liakos, A., Bekiari, E., Sinakos, E., & Τσάπας, Α. (2023) · HORMONES · doi:10.1007/s42000-023-00493-z · Cited by 15
Mantovani, A., & Targher, G. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-2021-13 · Cited by 15
Self-citationLaursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2132145 · Cited by 12
He, X., Li, Y., Ma, Y., Fu, Y., Xun, X., Cui, Y., & Dong, Z. (2022) · Molecules · doi:10.3390/molecules27196190 · Cited by 14
Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment
Che, W., Zhao, M., Li, X., Li, C., Cho, W. C. S., & Yu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1002916 · Cited by 14
“An updated meta-analysis of randomized controlled trials showed that GLP-1 receptor agonists reduce liver fat content and serum liver enzyme level, thus improving NAFLD (129).”
Anastasiou, G., Stefanakis, K., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156044 · Cited by 12
Borodavkin, P., Sheridan, W., Matta-Coelho, C., Oštarijaš, E., Zaïr, Z. M., Miras, A. D., McGowan, B. M., le Roux, C. W., Vincent, R. P., & Dimitriadis, G. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14565 · Cited by 14
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
Morieri, M. L., Targher, G., Lapolla, A., D'Ambrosio, M., Tadiotto, F., Rigato, M., Frison, V., Paccagnella, A., Simioni, N., Avogaro, A., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.049 · Cited by 15
Self-citationRelationship between MASLD and women’s health: A review
Jančová, P., Ismail, K. M., & Vištějnová, L. (2025) · Women s Health · doi:10.1177/17455057251376883 · Cited by 24
“63 In the recent clinical guidelines, neither metformin, liraglutide, nor sema-glutide was recommended for MASLD management; however, they were stated as safe to use in MASLD patients to target metabolic comorbidities.”
Asero, C., Giandalia, A., Cacciola, I., Morace, C., Lorello, G., Caspanello, A. R., Alibrandi, A., Squadrito, G., & Russo, G. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082858 · Cited by 11
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
Huynh, D. J., Renelus, B. D., & Jamorabo, D. S. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0814 · Cited by 19
“They have been shown to reduce liver inflammation, fibrosis and lipid oxidation [8,9] in preclinical studies, and they have lowered glycemic indices in human studies [10].”
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 17
Jun, H., Liu, S., Knights, A. J., Zhu, K., Ma, Y., Gong, J., Lenhart, A. E., Peng, X., Huang, Y., Ginder, J. P., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002728 · Cited by 12
Mahapatro, A., Bozorgi, A., Obulareddy, S. U. J., Jain, S. M., Korsapati, R. R., Kumar, A., Patel, K., Moghadam, S. S., Arya, A., Alotaibi, A. J., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002592 · Cited by 15
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 14
Semaglutide versus other GLP-1 receptor agonists in patients with MASLD
Kuo, C.-C., Li, C., Chuang, M., Huang, P., Kuo, H., & Lai, C. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000747 · Cited by 16
“[35,36] Our study also observed superior and sustained improvements in body weight loss with semaglutide throughout a 5-year follow-up period, further demonstrating its long-term benefits.”
Hussein, A., Awashra, A., Rajab, I. M., Bdair, M., Hamdan, D., Nouri, A., Khatib, E., Khatib, G., & Latt, N. L. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70075 · Cited by 13
“GLP-1 RAs, initially developed for type 2 diabetes management, have demonstrated hepatoprotective effects through mechanisms such as appetite suppression, improved glucose homeostasis and direct anti-inflammatory and antifibrotic properties in the liver [6].”
InfluentialSemaglutide in MASLD Patients: Improved Survival and Liver Outcomes
Suki, M., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., Alon, R., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18071075 · Cited by 13
“While several pharmacotherapies have been investigated, including vitamin E, pioglitazone, and obeticholic acid, until recently, none had received regulatory approval specifically for MASLD treatment, highlighting an urgent need for effective interventions [11].”
Khalifa, O., Mroué, K. H., Mall, R., Ullah, E., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10102652 · Cited by 10
Concepción‐Zavaleta, M. J., Fuentes‐Mendoza, J. M., Yovera, J. G. G., Ruvalcaba-Barbosa, G. Y., Cura-Rodríguez, L. D., González-Rodríguez, J. S., Urteaga, L. A. C., Pérez-Reyes, A. I., Aldave, J. E. Q., & Paz‐Ibarra, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.111435 · Cited by 18
Hachuła, M., Kosowski, M., Basiak, M., & Okopień, B. (2023) · Pharmaceuticals · doi:10.3390/ph16091190 · Cited by 10
“confirmed the effectiveness of various GLP1 receptor agonist in reducing the percentage of hepatic fat [47].”
BackgroundXie, J., & Wang, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001320 · Cited by 12
Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
Basile, L., Cannarella, R., Iuliano, S., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04103-9 · Cited by 11
Zaitoon, H., Lubetzky, R., Amir, A. Z., Moran‐Lev, H., Sagi, L., Bach, M. Y., Borger, O., Chorna, E., Lebenthal, Y., & Brener, A. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02109-9 · Cited by 12
García‐Compeán, D., Kumar, R., del Cueto-Aguilera, Á. N., Maldonado-Garza, H. J., & Villarreal‐Pérez, J. Z. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100751 · Cited by 12
Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients
Yen, F., Wei, J. C., Wang, C., Hou, M., Yu, T., Huang, Y., Hwu, C., & Hsu, C.-C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112174 · Cited by 9
Simeone, P., Costantino, S., Liani, R., Tripaldi, R., Castelnuovo, A. F. D., Tartaro, A., Mengozzi, A., Cosentino, F., Cipollone, F., Consoli, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02706-8 · Cited by 13
“It is also still debated whether different types of weight loss intervention (i.e. diet or GLP1-RA [13, 14]) have similar or different effects on MASLD status.”
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Ragghianti, B., Sbraccia, P., et al. (2025) · Obesity Facts · doi:10.1159/000546855 · Cited by 9
Wood, M., Kennedy, A. G., Khan, S., Hitt, J. R., Davis, K., Reddy, S. S., & Gilbert, M. P. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241253661 · Cited by 9
Alfieri, C., Molinari, P., Cinque, F., Vettoretti, S., Cespiati, A., Bignamini, D., Nardelli, L., Fracanzani, A. L., Castellano, G., & Lombardi, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147728 · Cited by 13
Mahmoud, A., Mohamed, I., Abuelazm, M. T., Ahmed, A. A. S., Saeed, A., Elshinawy, M. A., Almaadawy, O., & Abdelazeem, B. (2024) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2024.2335829 · Cited by 18
“39 Consequently, orlistat emerges as a promising treatment option, potentially offering synergistic effects when combined with dietary modification, weight loss, and exercise interventions, but further studies are still needed to confirm or refute these results.”
BackgroundChai, S.-Y., Zhang, R.-Y., Fernandes, G., Zheng, Y.-M., & Wei, L. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i46.113608 · Cited by 12
Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
Weiskirchen, R., & Lonardo, A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671694 · Cited by 10
Self-citationSamuel, S., Abulawi, A., & Malik, R. (2023) · Gastroenterology Insights · doi:10.3390/gastroent14030018 · Cited by 11
Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
Alfawaz, S. A., Burzangi, A. S., & Esmat, A. (2024) · Cureus · doi:10.7759/cureus.67080 · Cited by 16
“Recent studies have revealed that a staggering 30% of the general population has evidence of NAFLD and that it affects 70-80% of obese or diabetic patients [8,9].”
BackgroundBerković, M. C., Režić, T., Bilić-Čurčić, I., & Mrzljak, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i20.6759 · Cited by 10
Katsuyama, H., Hakoshima, M., Umeyama, S., Iida, S., Adachi, H., & Yanai, H. (2023) · Biomedicines · doi:10.3390/biomedicines11030869 · Cited by 9
“ΔBMI ΔHbA1c ΔTG ΔHDL-C ΔLDL-C ΔNon-HDL-C ΔHSI ΔNFS Δ BMI 1 Δ HbA1c 0.112 1 Δ TG −0.021 0.165 1 Δ HDL-C 0.245 * −0.236 * −0.121 1 Δ LDL-C 0.097 0.377 ** −0.233 0.215 1 Δ Non-HDL-C 0.046 0.398 ** 0.415 ** −0.040 0.518 ** 1 Δ HSI 0.586 ** 0.037 0.064 0.141 0.208 −0.026 1 Δ NFS 0.201 0.067 0.268 ** 0.013 −0.083 0.149 −0.2…”
BackgroundInfluentialSafety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients With Cirrhosis
Morris, S. M., Armstrong, M. J., & Newsome, P. N. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.023 · Cited by 10
Liu, B. D. X., Aly, M., Lin, C. H.-T., Panesar, N., Hill, H., & Qureshi, K. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.017 · Cited by 11
Borges, R. D. S., de Abreu, E. S., Berton, G. G., de Paula, L. H., Conegundes, A. F., Martins, J. M. B., Martins, M. A. B., Dahbour, A., Fernandes, M. V., & Abdelmalek, M. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101708 · Cited by 14
Exendin‐4 Attenuates Hepatic Steatosis by Promoting the Autophagy‐Lysosomal Pathway
Yu, H., Wang, H., Hsieh, M., Lee, M., Su, B., & Shan, Y. (2022) · BioMed Research International · doi:10.1155/2022/4246086 · Cited by 7
“Moreover, the GLP-1 receptor agonist exendin-4 has been considered as a potential therapeutic agent for several metabolic disorders, such as type 2 diabetes [17], NASH [18], diabetic cardiomyopathy [19], and obesity [20].”
Svane, M. S., Johannesen, H. H., Hansen, A. E., Martinussen, C., Bojsen-Møller, K. N., Hansen, M. L., Deacon, C. F., Keller, S. H., Klausen, T. L., Loft, A., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01207-y · Cited by 8
Scheen, A. J. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100145 · Cited by 7
Boutari, C., Hill, M. A., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156397 · Cited by 7
Grasset, E., Briand, F., Virgilio, N., Schön, C., Wilhelm, M. G., Cudennec, B., Ravallec, R., Aboubacar, H., Vleminckx, S., Prawitt, J., et al. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4538 · Cited by 9
“…and its comorbidities like fatty liver, dyslipidemia, nephropathy or peripheral neuropathy, particularly since GLP-1 based therapies have shown beneficial effects on these metabolic complications (Przezak, Bielka, and Pawlik 2021; Yaribeygi et al. 2021; Razavi et al. 2022; Mantovani et al. 2021).”
Mitochondrial targeted therapies in MAFLD
Lai, S., Tang, D., & Feng, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151498 · Cited by 11
Menekşe, B., & Batman, A. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0088 · Cited by 8
Dobbie, L. J., Cuthbertson, D. J., Hydes, T., Alam, U., & Zhao, S. S. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad068 · Cited by 6
Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes
Vázquez, L. A., Romera, I., Santos, M. R., & Escalada, J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01467-5 · Cited by 9
Causal effects of non-alcoholic fatty liver disease on osteoporosis: a Mendelian randomization study
Zhou, Y., Ni, Y., Wang, Z., Prud’homme, G. J., & Wang, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1283739 · Cited by 8
“Clinical evidence indicates that GLP-1RA contributes to an improvement of liver histology in NASH patients (51, 52).”
BackgroundGLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
Jiang, H., & Zang, L. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128283153231226103218 · Cited by 7
Semaglutide-Induced Liver Injury
Kalsi, H., Arora, S. S., Essilfie-Quaye, K., Bassi, R., Akhavan, N., Perbtani, Y., & Brar, T. S. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001776 · Cited by 6
Cui, J., Wang, W., Xu, Q., Zhu, M., Li, Y., Liu, Y., & Liu, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040775 · Cited by 6
Optimizing the liver transplant candidate
Kasia, C., & Duarte‐Rojo, A. (2024) · npj gut and liver. · doi:10.1038/s44355-024-00003-x · Cited by 8
Fetzner, J., & Rafi, E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae817 · Cited by 6
Zhang, J., Wang, Q., Zhou, N., Liu, J., Tao, L., Peng, Z., Hu, G., Wang, H., Fu, L., & Peng, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-94401-7 · Cited by 6
“Emerging evidence suggests that these agents can alleviate steatohepatitis and reduce cardiovascular risks, but their efficacy in improving liver fibrosis remains unsatisfactory 14–16 .”
Semaglutide: a game changer for metabolic diseases?
Milluzzo, A., Manuella, L., & Sciacca, L. (2022) · Exploration of Medicine · doi:10.37349/emed.2022.00083 · Cited by 8
Somabattini, R. A., Sherin, S., Siva, B., Chowdhury, N., & Nanjappan, S. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122806 · Cited by 8
Pancreatic hormones: insulin and glucagon
Litwack, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90262-5.00022-6 · Cited by 6
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
Kalinkova, M., Kadiyska, T., & Handjieva‐Darlenska, T. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e104481 · Cited by 6
“Moreover, several studies have shown a positive role of GLP1Rs in treatment of fatty liver disease, which also has an impact on glucose homeostasis (Mantovani et al. 2021).”
BackgroundPieralice, S., Amendolara, R., Berna, V., Manganaro, G., Zurru, A., D’Onofrio, L., Risi, R., Alfonsi, M., Maddaloni, E., & Buzzetti, R. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s528569 · Cited by 10
“90 Finally, GLP-1-GIP agonists (eg, tirzepatide), dual GLP-1-glucagon agonists (eg, cotadutide, survodutide, efinopeg-dutide), and triple GLP-1-GIP-glucagon agonists (eg, retatrutide) are drugs with an emerging role in the treatment for MASH.”
Ng, N. B. H., Sng, A. A., & Huang, J. G. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i1.111211 · Cited by 6
The versatile interplay between steatotic liver disease and liver cancer
Rahbari, M., Gris‐Oliver, A., Ramadori, P., Aicher, D., Sia, D., MALEK, N. P., Loomba, R. S., Bataller, R. A., Llovet, J. M., & Heikenwälder, M. F. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00918-y · Cited by 4
“GLP1RAs, such as semaglutide and liraglutide, lead to weight loss and thus improve systemic metabolism, and reduce hepatic steatosis by enhancing insulin sensitivity and lowering systemic inflammation 208 .”
HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial
Guo, L., Sun, Z., Zhang, L., Qin, G., Li, Y., Chen, X., Xu, N., Su, X., Li, M. T., Sun, J., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.15622 · Cited by 5
Immunology and treatments of fatty liver disease
Tang, S., Wu, S., Zhang, W., Ma, L., Zuo, L., & Wang, H. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03920-1 · Cited by 6
“Agonists of the GLP-1 receptor (GLP-1R) or GLP-1 analogs have shown therapeutic efficacy in the treatment of obesity NASH and ALD (Arvanitakis et al. 2022; Ding et al. 2006; Hinnen 2017; Mahalingam et al. 2023; Mantovani et al. 2021; Patel Chavez et al. 2022).”
Metadata
- Authors
- Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G.
- Affiliations
- University of Verona (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Corresponding author
- Targher, Giovanni
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2021-01-27
- Volume
- 11
- Issue
- 2
- Pages
- 73
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC7911747
- OpenAlex
- W3126030429
- Cited by
- 299
- References
- 68
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 54 · 2023: 61 · 2022: 61 · 2021: 35
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- GLP-1 receptor agonists, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liraglutide, semaglutide, exenatide, dulaglutide, liver fat, liver enzymes, liver fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.